Live Breaking News & Updates on சாங் குங் மருத்துவ அடித்தளம்
Stay updated with breaking news from சாங் குங் மருத்துவ அடித்தளம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intuitive is Advancing Robotic-assisted Surgery in Taiwan - Taiwan Business TOPICS amcham.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from amcham.com.tw Daily Mail and Mail on Sunday newspapers.
2021/05/27 13:57 Herbal supplement NRICM101 Herbal supplement NRICM101 (CNA photo) TAIPEI (Taiwan News) Taiwan-based Sun Ten Pharmaceutical Co. (順天堂) announced Wednesday (May 26) its donation to hospitals of the first batch of a herbal drug touted as being able to treat COVID-19. Developed by the National Research Institute of Chinese Medicine (NRICM) in 2020, the treatment NRICM101 (清冠一號) contains 10 herbs, including mint, Chinese skullcap, houttuynia, and licorice. The product has proven effective at inhibiting coronavirus replication and preventing the cytokine storm, in which the body attacks its own cells. It s said to be able to reduce the chance of severe illness in coronavirus patients without side effects, according to NRICM. ....
Science for just $15 USD. Don’t risk it Mammograms are a common but imperfect way of assessing breast cancer risk. Current U.S. breast cancer screening guidelines all use a component of cancer risk assessment to inform clinical course. Yala et al. developed a machine learning model called “Mirai” to predict breast cancer risk based on traditional mammograms. The authors’ risk model performed better than Tyrer-Cuzick and previous deep learning models at identifying both 5-year breast cancer risk and high-risk patients across multiple international cohorts. Mirai also performed similarly across race and ethnicity categories, suggesting the potential for improvement in patient care across the board. ....
NHRI Vice President Sytwu Huey-kang. CNA file photo Taipei, Jan. 15 (CNA) The Central Epidemic Command Center (CECC) is planning to launch a public-private partnership to develop and produce antibody treatments against COVID-19, according to the National Health Research Institutes (NHRI). Speaking to the media on Friday, NHRI Vice President Sytwu Huey-kang (司徒惠康) said the treatments, which will be used to treat COVID-19 patients and also provide short-term immunity for healthy individuals, are seen as a vital stopgap treatment until vaccines become widely available. Sytwu said the NHRI, Academia Sinica, National Taiwan University Hospital and Chang Gung Medical Foundation each began working to develop COVID-19 antibody treatments last year, but their efforts have been largely uncoordinated. ....